Adjuvant chemotherapy device for evaluating diversified breast cancers

Abstract

The invention relates to the technical field of adjuvant chemotherapy, and discloses an adjuvant chemotherapy device for evaluating diversified breast cancers. The adjuvant chemotherapy device for evaluating the diversified breast cancers comprises a bottom plate, a cabinet body, a worktable, a rotating table, a rotating driving mechanism, ten position stabilizing mechanisms, a vacuum adsorption mechanism and ten test tube placement mechanisms, wherein the cabinet body is fixed to the top of the bottom plate; the worktable is fixed to the top of the cabinet body; the rotating table is movablyconnected to the middle part of the top of the worktable; the rotating driving mechanism is arranged on the inner top wall of the cabinet body; and the ten position stabilizing mechanisms are circumferentially and equidistantly fixed to the outer side of the top of the rotating table. According to the adjuvant chemotherapy device for evaluating the diversified breast cancers, a vacuum state is enabled to be formed on the inner part of a sealing cover, a blood sample is prevented from being affected by an external environment, the problem of blood contamination is avoided, the placement and maintenance of the blood sample are facilitated, the accuracy of the detection results of peripheral blood circulation biomarkers is ensured, and meanwhile, the efficiency of blood sample immunostainingis improved.

Description

technical field [0001] The invention relates to the technical field of adjuvant chemotherapy, in particular to an adjuvant chemotherapy device for evaluating multiple breast cancers. Background technique [0002] Patients with locally advanced breast cancer or early breast cancer with high-risk factors need to receive neoadjuvant chemotherapy. Neoadjuvant chemotherapy requires peripheral blood circulation biomarkers (including circulating endothelial cells) before treatment, during treatment and before surgery. and subtypes, myeloid-derived suppressor cells, peripheral blood lymphocyte subsets, and circulating tumor DNA) to provide important references for optimizing the treatment of breast cancer. When the blood samples of 24 patients were collected, It takes a period of time to complete the blood sample detection, and then the blood sample is easily affected by the external environment, which will cause blood pollution and cause inaccurate detection results of peripheral b...

AI Technical Summary

Problems solved by technology

[0002] Patients with locally advanced breast cancer or early breast cancer with high-risk factors need to receive neoadjuvant chemotherapy. Neoadjuvant chemotherapy requires peripheral blood circulation biomarkers (including circulating endothelial cells) before treatment, during treatment and before surgery. and subtypes, myeloid-derived suppressor cells, peripheral blood lymphocyte subsets, and circulating tumor DNA) to provide important references for optimizing the treatment of breast cancer. When the blood samples of 24 patients were collected, It takes a period of time to complete the blood sample detection, and then the blood sample is easily affected by the external environment, which will cause blood pollution and cause inaccurate detection results of peripheral blood circulation biomarkers. Therefore, the blood sample needs to be vacuum isolated. However, the blood sample Under pressure reduction or negative pressure conditions, the surrounding pressure of the blood sample decreases or disappears, the resistance of molecular movement in the blood decreases, and the Van der Waals force is not enough to make the molecules in the blood attract together and disperse away from the attraction of the Van der Waals force. It will gradually change from liquid to gas, which will make blood samples unusable, which will affect the diagnosis of breast cancer treatment results

Images